Nevro (NVRO) Set to Announce Quarterly Earnings on Monday

Nevro (NYSE:NVRO - Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Monday, November 11th. Analysts expect the company to announce earnings of ($0.82) per share for the quarter. Nevro has set its FY 2024 guidance at EPS.Parties interested in registering for the company's conference call can do so using this link.

Nevro (NYSE:NVRO - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.10. Nevro had a negative return on equity of 24.89% and a negative net margin of 18.17%. The business had revenue of $104.16 million for the quarter, compared to analyst estimates of $107.11 million. During the same period in the previous year, the company posted ($0.69) EPS. The company's revenue was down 4.3% compared to the same quarter last year. On average, analysts expect Nevro to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nevro Trading Down 3.3 %

NYSE NVRO traded down $0.18 during mid-day trading on Monday, hitting $5.35. The company's stock had a trading volume of 514,780 shares, compared to its average volume of 547,291. The firm has a market capitalization of $199.45 million, a P/E ratio of -2.60 and a beta of 0.93. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.77 and a quick ratio of 3.53. Nevro has a 52-week low of $4.38 and a 52-week high of $22.64. The stock's fifty day simple moving average is $5.31 and its two-hundred day simple moving average is $7.77.

Wall Street Analyst Weigh In

Several research firms recently weighed in on NVRO. Robert W. Baird reduced their target price on shares of Nevro from $11.00 to $8.00 and set a "neutral" rating on the stock in a report on Wednesday, August 7th. Royal Bank of Canada lowered their target price on Nevro from $16.00 to $7.00 and set a "sector perform" rating for the company in a research note on Wednesday, August 7th. Morgan Stanley reduced their price target on Nevro from $14.00 to $9.00 and set an "equal weight" rating on the stock in a research report on Monday, July 15th. Citigroup decreased their price target on Nevro from $6.89 to $6.00 and set a "neutral" rating for the company in a report on Tuesday, October 1st. Finally, Piper Sandler reduced their target price on shares of Nevro from $12.00 to $7.00 and set an "underweight" rating on the stock in a research report on Wednesday, August 7th. Three research analysts have rated the stock with a sell rating and twelve have assigned a hold rating to the company. According to MarketBeat.com, Nevro currently has an average rating of "Hold" and a consensus target price of $9.80.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.